Hi! Welcome Back and Stay Tune! Malaysia to deliberate on AstraZeneca vaccine over 'very rare' blood clots link - Mukah Pages : Media Marketing Make Easy With 24/7 Auto-Post System. Find Out How It Was Done!

Header Ads

Malaysia to deliberate on AstraZeneca vaccine over 'very rare' blood clots link


 


The Covid-19 vaccine committee will deliberate on whether to use the AstraZeneca vaccine after European Union Regulators found a link between it and "very rare" cases of blood clots.

"The committee will deliberate on the matter and decide if we will go ahead with using AstraZeneca in our portfolio of vaccines.

"Safety is paramount," said de facto Covid-19 Vaccination Minister Khairy Jamaluddin.

Yesterday, the European Medicines Agency (EMA) said it was "reminding healthcare professionals and people receiving the (AstraZeneca) vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within two weeks of vaccination".

The EMA had received reports of 169 cases of the rare brain blood clot by early this month, after 34 million doses of the vaccine were administered in the EU.

In comparison, four women out of 10,000 would get a blood clot from taking oral contraception.

A British government advisory group also said the AstraZeneca vaccine should not be given to those under 30 where possible out of "the most utmost caution".

Malaysia is supposed to receive a shipment of 600,000 doses of the AstraZenecava vaccine in June. - Mkini



✍ Credit given to the original owner of this post : ☕ Malaysians Must Know the TRUTH

🌐 Hit This Link To Find Out More On Their Articles...🏄🏻‍♀️ Enjoy Surfing!




No comments

Comments are welcome and encouraged on this site. Comments deemed to be spam or solely promotional will be deleted. Including link to relevant content is permitted, but comments should be relevant to the post topic.

Comments including profanity and containing language that could deemed offensive will also deleted. Please respectful toward other contributors. Thank you.